SRPTHealthcare · BiotechnologyThe 24 Wall Street analysts covering Sarepta Therapeutics, Inc. hold a median 12-month price target of $20 — +5.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 4 Nov 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Sarepta Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Growth (28): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SRPT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +5.3% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Oct 2026 | RBC Capital | Maintains | Sector Perform | $19 → $17 |
| 5 Oct 2026 | HC Wainwright & Co. | Reiterates | Sell | $5.00 |
| 30 Sept 2026 | JP Morgan | Maintains | Neutral | — |
| 30 Sept 2026 | JP Morgan | Maintains | Neutral | $23 → $20 |
| 28 Sept 2026 | Needham | Reiterates | Underperform | — |
| 28 Sept 2026 | Needham | Reiterates | Underperform | — |
| 9 July 2026 | Piper Sandler | Maintains | Neutral | $23 → $20 |
| 9 July 2026 | Piper Sandler | Maintains | Neutral | — |
| 9 July 2026 | Wolfe Research | Upgrade | Outperform | $27 |
| 9 July 2026 | Wolfe Research | Upgrade | Outperform | — |
| 16 Apr 2026 | HC Wainwright & Co. | Reiterates | Sell | — |
| 26 Mar 2026 | Citigroup | Maintains | Sell | — |
| 26 Mar 2026 | Needham | Reiterates | Underperform | — |
| 19 Mar 2026 | Oppenheimer | Reiterates | Outperform | — |
| 13 Mar 2026 | Mizuho | Maintains | Outperform | — |
| 10 Mar 2026 | Citigroup | Maintains | Sell | — |
| 2 Mar 2026 | HC Wainwright & Co. | Reiterates | Sell | — |
| 27 Feb 2026 | Wells Fargo | Maintains | Overweight | — |
| 27 Jan 2026 | HC Wainwright & Co. | Reiterates | Sell | — |
| 23 Jan 2026 | Wedbush | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SRPT appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Sarepta Therapeutics, Inc. returned +17.3% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 16% of US stocks
Cheaper than 68% of US stocks
Cheaper than 60% of US stocks
Cheaper than 97% of US stocks
Higher than 8% of US stocks
Higher than 15% of US stocks
Higher than 76% of US stocks
Higher than 70% of US stocks
Higher than 22% of US stocks
Higher than 36% of US stocks
Higher than 39% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Sarepta Therapeutics, Inc. has a market value of $2.0B and an enterprise value of $2.2B.
Revenue in the twelve months to 30 June 2026: $2.0B. The latest quarter shrank 34.3% year on year.
Net income over the same four quarters: −$136.7M, a −6.9% net margin.
Diluted earnings per share, trailing twelve months: $−2.90.
Free cash flow in the twelve months to 30 June 2026: $75.0M.
Trailing P/E: 45.5×; forward P/E: 7.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Sarepta Therapeutics, Inc. employs 835 people — $2.4M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Sarepta Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research says Sarepta Therapeutics lacks the combination of factors it considers supportive of a likely earnings beat in the upcoming report. The article points readers to its key expectations for the report.
Why it matters — SRPT watchers may note the article’s assessment of the company’s prospects for an earnings beat ahead of its upcoming report.
Sarepta Therapeutics announced that senior management will participate in two investor conferences on Nov. 9, 2026: the Wolfe Research Healthcare Conference in New York City and the Guggenheim Securities Healthcare Innovation Conference in Boston. The Guggenheim presentation will include a 3 p.m. ET fireside chat and will be webcast live.
Why it matters — The appearances provide SRPT watchers with scheduled opportunities to hear from company management, including a webcast presentation.
Sarepta Therapeutics said it will report third-quarter 2026 financial results after the Nasdaq Global Market closes on Nov. 5, 2026, followed by a conference call at 4:30 p.m. ET. The call will be webcast live through the company’s investor relations website.
Why it matters — SRPT watchers can follow the company’s upcoming quarterly results and management discussion via the webcast.
Sarepta presented preclinical data at the Oligonucleotide Therapeutics Society annual meeting showing that investigational siRNA program SRP-1003 can reduce pathogenic DMPK transcripts in the nucleus in DM1.
Why it matters — The findings concern SRP-1003’s preclinical activity against a molecular driver of DM1, an area relevant to Sarepta’s development program.
The law firm Kahn Swick & Foti announced it has commenced an investigation into the officers and directors of Sarepta Therapeutics. The firm, led by former Louisiana Attorney General Charles C. Foti Jr., is examining the biopharmaceutical company, whose most important product is Elevidys for Duchenne muscular dystrophy.
Why it matters — An investigation into Sarepta's officers and directors could signal potential legal or governance concerns for SRPT shareholders.
The 24 Wall Street analysts covering Sarepta Therapeutics, Inc. have a median 12-month price target of $20, with estimates ranging from $5 to $38. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 24 analysts covering Sarepta Therapeutics, Inc., 7 rate it a Buy, 12 a Hold and 5 a Sell. Ticker Nerd's systematic factor model ranks Sarepta Therapeutics, Inc. 72 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Sarepta Therapeutics, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).
No one can know that. What the data says: the median 12-month target from 24 analysts implies +5.3% from the last close, and Ticker Nerd's factor model ranks Sarepta Therapeutics, Inc. 72 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Sarepta Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SRPT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $38 over the next 12 months.
Sarepta Therapeutics, Inc. returned +17.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare diseases, with a strong emphasis on rare neuromuscular disorders.
The most recent item we track (Zacks Investment Research, 29 Oct 2026): "Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?". Zacks Investment Research says Sarepta Therapeutics lacks the combination of factors it considers supportive of a likely earnings beat in the upcoming report. The article points readers to its key expectations for the report.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare diseases, with a strong emphasis on rare neuromuscular disorders. The company develops RNA-targeted therapeutics, siRNA-based treatments, gene therapies, and other genetic medicine modalities designed to address underlying disease mechanisms. Its current portfolio includes approved and commercialized therapies for Duchenne muscular dystrophy, along with additional programs in development for other rare genetic conditions. Sarepta Therapeutics also maintains a broader research and manufacturing platform centered on advancing genetic medicine from discovery through delivery. Based in Cambridge, Massachusetts, the company plays a notable role in the rare disease market by combining therapeutic innovation with a specialized focus on patients who often have limited treatment options.
CEO Dr. Michael E. Severino M.D. · 835 employees · United States · https://www.sarepta.com
